Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Update

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the recipient of a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 718,008 shares, a growth of 172.4% from the June 30th total of 263,542 shares. Currently, 4.6% of the shares of the company are sold short. Based on an average daily volume of 399,680 shares, the days-to-cover ratio is currently 1.8 days.

Cel-Sci Stock Performance

NYSEAMERICAN:CVM traded up $0.02 during midday trading on Tuesday, reaching $1.20. The stock had a trading volume of 144,419 shares, compared to its average volume of 273,209. The company has a debt-to-equity ratio of 0.64, a current ratio of 0.60 and a quick ratio of 0.54. Cel-Sci has a 1-year low of $0.89 and a 1-year high of $13.48. The firm’s fifty day simple moving average is $1.25 and its 200-day simple moving average is $3.08. The stock has a market capitalization of $20.98 million, a P/E ratio of -0.12 and a beta of 0.64.

Cel-Sci (NYSEAMERICAN:CVM) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.67) EPS for the quarter.

Institutional Trading of Cel-Sci

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Cel-Sci by 59.7% in the third quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock valued at $2,692,000 after acquiring an additional 109,352 shares during the period. Bank of America Corp DE raised its holdings in shares of Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock valued at $94,000 after buying an additional 39,190 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Cel-Sci by 133.0% during the first quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock worth $115,000 after purchasing an additional 20,484 shares in the last quarter. Geode Capital Management LLC boosted its position in Cel-Sci by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock valued at $417,000 after buying an additional 18,432 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Cel-Sci in the fourth quarter worth about $83,000. 12.08% of the stock is currently owned by institutional investors.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.